{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:08:50Z","timestamp":1791389330884,"version":"4.3.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Epigenetic modulators of the histone deacetylase (HDAC) family control key biological processes and are frequently dysregulated in cancer. There is superior activity of HDAC inhibitors (HDACi) in patients with myeloproliferative neoplasms (MPNs) that carry the Janus kinase-2 point mutant JAK2\n                    <jats:sup>V617F<\/jats:sup>\n                    . This constitutively active tyrosine kinase activates signal-transducer-and-activator-of-transcription (STAT) transcription factors to promote cell proliferation and inflammatory processes. We reveal that the inhibition of HDAC1\/HDAC2 with the clinically advanced HDACi romidepsin, the experimental HDACi entinostat and MERCK60, and genetic depletion of HDAC1\/HDAC2 induce apoptosis and long-term growth arrest of primary and permanent MPN cells in vitro and in vivo. This treatment spares normal hematopoietic stem cells and does not compromise blood cell differentiation. At the molecular level, HDAC1 and HDAC2 control the protein stability of SIAH2 through acetylation. Genetic knockout experiments show that SIAH2 accelerates the proteasomal degradation of JAK2\n                    <jats:sup>V617F<\/jats:sup>\n                    in conjunction with the E2 ubiquitin-conjugating enzyme UBCH8. SIAH2 binds to the surface-exposed SIAH degron motif VLP1002 in the catalytic domain of JAK2\n                    <jats:sup>V617F<\/jats:sup>\n                    . At the functional level, SIAH2 knockout MPN cells are significantly less sensitive to HDACi. Global RNA sequencing verifies that JAK-STAT signaling is a prime target of SIAH2. Moreover, HDAC1 is an adverse prognostic factor in patients with acute myeloid leukemia (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009150,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02), being a possible complication of MPNs. These insights reveal a previously unappreciated link between HDAC1\/HDAC2 as key molecular targets, the still undefined regulation of cytoplasmic-to-nuclear signaling by HDACs, and how HDACi kill JAK2\n                    <jats:sup>V617F<\/jats:sup>\n                    -positive cells from MPN patients and mice with JAK2\n                    <jats:sup>V617F<\/jats:sup>\n                    in vitro and in vivo.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02369-7","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T23:02:04Z","timestamp":1756422124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The deacetylases HDAC1\/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-2573","authenticated-orcid":false,"given":"Al-Hassan M.","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-9380","authenticated-orcid":false,"given":"Marten A.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina M.","family":"Schn\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanira","family":"Zeyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Lossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Muth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P.","family":"Radsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-6212","authenticated-orcid":false,"given":"Walburgis","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Christmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-045X","authenticated-orcid":false,"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2369_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","volume":"39","author":"F Perner","year":"2025","unstructured":"Perner, F. et al. Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia 39, 1011\u20131030 (2025).","journal-title":"Leukemia"},{"key":"2369_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/pharmrev.122.000612","volume":"75","author":"AM Mustafa","year":"2023","unstructured":"Mustafa, A. M. & Kr\u00e4mer, O. H. Pharmacological modulation of the crosstalk between aberrant janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer. Pharm. Rev. 75, 35\u201361 (2023).","journal-title":"Pharm. Rev."},{"key":"2369_CR3","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"2369_CR4","doi-asserted-by":"publisher","first-page":"15190","DOI":"10.1073\/pnas.1401873111","volume":"111","author":"E Chen","year":"2014","unstructured":"Chen, E. et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc. Natl. Acad. Sci. USA 111, 15190\u201315195 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2369_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","volume":"588","author":"AK Jayavelu","year":"2020","unstructured":"Jayavelu, A. K. et al. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 588, 157\u2013163 (2020).","journal-title":"Nature"},{"key":"2369_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843\u2013862 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2369_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3324\/haematol.2023.283987","volume":"110","author":"VY Ling","year":"2025","unstructured":"Ling, V. Y. et al. Pathogenesis and management of high molecular risk myeloproliferative neoplasms. Haematologica 110, 863\u2013876 (2025).","journal-title":"Haematologica"},{"key":"2369_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11899-024-00744-9","volume":"19","author":"K Thaw","year":"2024","unstructured":"Thaw, K. et al. JAK inhibitors for myelofibrosis: strengths and limitations. Curr. Hematol. Malig. Rep. 19, 264\u2013275 (2024).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2369_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2159-8290.CD-22-0952","volume":"14","author":"AJ Dunbar","year":"2024","unstructured":"Dunbar, A. J. et al. Jak2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms. Cancer Discov. 14, 737\u2013751 (2024).","journal-title":"Cancer Discov."},{"key":"2369_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03697-6","volume":"12","author":"S Bahl","year":"2021","unstructured":"Bahl, S. et al. EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function. Cell Death Dis. 12, 469 (2021).","journal-title":"Cell Death Dis."},{"key":"2369_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1021\/acs.accounts.3c00801","volume":"57","author":"DW Christianson","year":"2024","unstructured":"Christianson, D. W. Chemical versatility in catalysis and inhibition of the class IIb histone deacetylases. Acc. Chem. Res 57, 1135\u20131148 (2024).","journal-title":"Acc. Chem. Res"},{"key":"2369_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","volume":"29","author":"HT Chifotides","year":"2020","unstructured":"Chifotides, H. T. et al. Givinostat: an emerging treatment for polycythemia vera. Expert Opin. Investig. Drugs 29, 525\u2013536 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2369_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.leu.2405049","volume":"22","author":"V Guerini","year":"2008","unstructured":"Guerini, V. et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22, 740\u2013747 (2008).","journal-title":"Leukemia"},{"key":"2369_CR14","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","volume":"119","author":"H Akada","year":"2012","unstructured":"Akada, H. et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood 119, 3779\u20133789 (2012).","journal-title":"Blood"},{"key":"2369_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bjh.12416","volume":"162","author":"CL Andersen","year":"2013","unstructured":"Andersen, C. L. et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br. J. Haematol. 162, 498\u2013508 (2013).","journal-title":"Br. J. Haematol."},{"key":"2369_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1182\/blood.2019895326","volume":"135","author":"L Yue","year":"2020","unstructured":"Yue, L. et al. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood 135, 191\u2013207 (2020).","journal-title":"Blood"},{"key":"2369_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/leu.2012.284","volume":"27","author":"OH Kr\u00e4mer","year":"2013","unstructured":"Kr\u00e4mer, O. H. et al. SIAH proteins: critical roles in leukemogenesis. Leukemia 27, 792\u2013802 (2013).","journal-title":"Leukemia"},{"key":"2369_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl, C. & Dikic, I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366, 818\u2013822 (2019).","journal-title":"Science"},{"key":"2369_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","volume":"96","author":"V Wachholz","year":"2022","unstructured":"Wachholz, V. et al. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch. Toxicol. 96, 177\u2013193 (2022).","journal-title":"Arch. Toxicol."},{"key":"2369_CR20","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1128\/MCB.23.24.9150-9161.2003","volume":"23","author":"IJ Frew","year":"2003","unstructured":"Frew, I. J. et al. Generation and analysis of Siah2 mutant mice. Mol. Cell Biol. 23, 9150\u20139161 (2003).","journal-title":"Mol. Cell Biol."},{"key":"2369_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.biocel.2018.07.012","volume":"103","author":"SB Kokate","year":"2018","unstructured":"Kokate, S. B. et al. Testin and filamin-C downregulation by acetylated Siah2 increases invasiveness of Helicobacter pylori-infected gastric cancer cells. Int. J. Biochem. Cell Biol. 103, 14\u201324 (2018).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2369_CR22","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1096\/fj.201701344RRR","volume":"32","author":"SB Kokate","year":"2018","unstructured":"Kokate, S. B. et al. Acetylation-mediated Siah2 stabilization enhances PHD3 degradation in Helicobacter pylori-infected gastric epithelial cancer cells. FASEB J. 32, 5378\u20135389 (2018).","journal-title":"FASEB J."},{"key":"2369_CR23","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1021\/acs.jmedchem.7b01593","volume":"61","author":"A Sellmer","year":"2018","unstructured":"Sellmer, A. et al. Marbostat-100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors. J. Med. Chem. 61, 3454\u20133477 (2018).","journal-title":"J. Med. Chem."},{"key":"2369_CR24","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","volume":"21","author":"MC Stubbs","year":"2015","unstructured":"Stubbs, M. C. et al. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin. Cancer Res. 21, 2348\u20132358 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2369_CR25","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal, R. et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc. Natl. Acad. Sci. USA 111, E5401\u2013E5410 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2369_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1101\/gad.479209","volume":"23","author":"OH Kr\u00e4mer","year":"2009","unstructured":"Kr\u00e4mer, O. H. et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 23, 223\u2013235 (2009).","journal-title":"Genes Dev."},{"key":"2369_CR27","doi-asserted-by":"publisher","first-page":"27333","DOI":"10.1074\/jbc.M111.218214","volume":"286","author":"M Scortegagna","year":"2011","unstructured":"Scortegagna, M. et al. USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains. J. Biol. Chem. 286, 27333\u201327341 (2011).","journal-title":"J. Biol. Chem."},{"key":"2369_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03096-0","volume":"9","author":"A G\u00f6der","year":"2018","unstructured":"G\u00f6der, A. et al. HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130. Nat. Commun. 9, 764 (2018).","journal-title":"Nat. Commun."},{"key":"2369_CR29","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00204-018-2229-5","volume":"92","author":"N Kiweler","year":"2018","unstructured":"Kiweler, N. et al. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Arch. Toxicol. 92, 2227\u20132243 (2018).","journal-title":"Arch. Toxicol."},{"key":"2369_CR30","doi-asserted-by":"publisher","first-page":"e1010376","DOI":"10.1371\/journal.pgen.1010376","volume":"18","author":"L Hess","year":"2022","unstructured":"Hess, L. et al. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation. PLoS Genet. 18, e1010376 (2022).","journal-title":"PLoS Genet."},{"key":"2369_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108681","volume":"27","author":"A Tammaro","year":"2024","unstructured":"Tammaro, A. et al. HDAC1\/2 inhibitor therapy improves multiple organ systems in aged mice. iScience 27, 108681 (2024).","journal-title":"iScience"},{"key":"2369_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-025-02285-w","volume":"10","author":"L Yang","year":"2025","unstructured":"Yang, L. et al. Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I\/IIb inhibitor, in relapsed\/refractory multiple myeloma and lymphoma. Sig. Transduct. Target Ther. 10, 201 (2025).","journal-title":"Sig. Transduct. Target Ther."},{"key":"2369_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1126\/science.abn8933","volume":"376","author":"CR Glassman","year":"2022","unstructured":"Glassman, C. R. et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science 376, 163\u2013169 (2022).","journal-title":"Science"},{"key":"2369_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3390\/cancers11101436","volume":"11","author":"M Beyer","year":"2019","unstructured":"Beyer, M. et al. HDAC3 activity is essential for human leukemic cell growth and the expression of \u03b2-catenin, MYC, and WT1. Cancers 11, 1436 (2019).","journal-title":"Cancers"},{"key":"2369_CR35","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1038\/s41375-025-02612-8","volume":"39","author":"AO Mieland","year":"2025","unstructured":"Mieland, A. O. et al. The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells. Leukemia 39, 1756\u20131768 (2025).","journal-title":"Leukemia"},{"key":"2369_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1101\/gad.364306","volume":"20","author":"OH Kr\u00e4mer","year":"2006","unstructured":"Kr\u00e4mer, O. H. et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 20, 473\u2013485 (2006).","journal-title":"Genes Dev."},{"key":"2369_CR37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584\u2013596 (2010).","journal-title":"Cancer Cell"},{"key":"2369_CR38","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011","unstructured":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the care and use of laboratory animals. 8th edn, (National Academies Press (US): Washington (DC), 2011).","edition":"8th edn"},{"key":"2369_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42826-019-0031-z","volume":"36","author":"KH Lee","year":"2020","unstructured":"Lee, K. H. et al. The \u2018R\u2019principles in laboratory animal experiments. Lab Anim. Res 36, 1\u20133 (2020).","journal-title":"Lab Anim. Res"},{"key":"2369_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117076","volume":"177","author":"C Hieber","year":"2024","unstructured":"Hieber, C. et al. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells. Biomed. Pharmacother. 177, 117076 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"2369_CR41","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1038\/s41375-024-02405-5","volume":"38","author":"M Halilovic","year":"2024","unstructured":"Halilovic, M. et al. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins. Leukemia 38, 2561\u20132572 (2024).","journal-title":"Leukemia"},{"key":"2369_CR42","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1038\/onc.2011.68","volume":"30","author":"H J\u00e4kel","year":"2011","unstructured":"J\u00e4kel, H. et al. Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control. Oncogene 30, 3502\u20133512 (2011).","journal-title":"Oncogene"},{"key":"2369_CR43","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/leu.2010.114","volume":"24","author":"M Buchwald","year":"2010","unstructured":"Buchwald, M. et al. Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia 24, 1412\u20131421 (2010).","journal-title":"Leukemia"},{"key":"2369_CR44","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1038\/onc.2015.495","volume":"35","author":"C Garc\u00eda-Limones","year":"2016","unstructured":"Garc\u00eda-Limones, C. et al. CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2. Oncogene 35, 4289\u20134301 (2016).","journal-title":"Oncogene"},{"key":"2369_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105691119","volume":"119","author":"J Doffo","year":"2022","unstructured":"Doffo, J. et al. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc. Natl. Acad. Sci. USA 119, e2105691119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2369_CR46","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"2369_CR47","doi-asserted-by":"publisher","first-page":"D368","DOI":"10.1093\/nar\/gkad1011","volume":"52","author":"M Varadi","year":"2023","unstructured":"Varadi, M. et al. AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic Acids Res. 52, D368\u2013D375 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2369_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."},{"key":"2369_CR49","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2014","unstructured":"Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512\u2013D520 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2369_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2369_CR51","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao, Y. et al. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).","journal-title":"Nucleic Acids Res."},{"key":"2369_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I. et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."},{"key":"2369_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/C5MB00663E","volume":"12","author":"G Yu","year":"2016","unstructured":"Yu, G. & He, Q.-Y. ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol. Biosyst. 12, 477\u2013479 (2016).","journal-title":"Mol. Biosyst."},{"key":"2369_CR54","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G. et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"2369_CR55","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.7717\/peerj-cs.67","volume":"2","author":"J Anaya","year":"2016","unstructured":"Anaya, J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput. Sci 2, e67 (2016).","journal-title":"PeerJ Comput. Sci"},{"key":"2369_CR56","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z. et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013w560 (2019).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02369-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:17:04Z","timestamp":1757420224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02369-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02369-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.H.K. declares paid consultant activity for BASF, Ludwigshafen, Germany, and the patents \u201cThe use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity\u201d, \u201cNovel HDAC6 inhibitors and their uses\u201d, and \u201cSynthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors\u201d. The BASF did not influence the study, and its products are not discussed in this work. All the other authors declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}